drug_type
RELEVANT_DRUG
intervention_type
small-molecule TKI
drug_description
First-generation small-molecule BCR-ABL1 tyrosine kinase inhibitor (also inhibits KIT and PDGFR) that blocks leukemic cell proliferation and survival.
nci_thesaurus_concept_id
C62035
nci_thesaurus_preferred_term
Imatinib
nci_thesaurus_definition
An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.
drug_mesh_term
Imatinib Mesylate
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
ATP-competitive tyrosine kinase inhibitor that targets BCR-ABL1 and also inhibits KIT and PDGFR, blocking oncogenic signaling to suppress proliferation and induce apoptosis of leukemic cells (e.g., Ph+ ALL/CML).
drug_name
Imatinib
nct_id_drug_ref
NCT06061094